A share price of Emergent Biosolutions Inc [EBS] is currently trading at $9.89, down -0.30%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The EBS shares have gain 7.62% over the last week, with a monthly amount glided 19.73%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Emergent Biosolutions Inc [NYSE: EBS] stock has seen the most recent analyst activity on December 30, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $15. Previously, Rodman & Renshaw started tracking the stock with Buy rating on August 22, 2024, and set its price target to $16. On March 07, 2024, upgrade upgraded it’s rating to Buy but maintained its price target of $5 on the stock. The Benchmark Company downgraded its rating to a Hold. The Benchmark Company upgraded its rating to Buy for this stock on April 10, 2023, but kept the price target unchanged to $22. In a note dated March 17, 2023, JP Morgan downgraded an Underweight rating on this stock and revised its target price from $23 to $9.
Emergent Biosolutions Inc experienced fluctuations in its stock price throughout the past year between $4.02 and $12.73. Currently, Wall Street analysts expect the stock to reach $51.5 within the next 12 months. Emergent Biosolutions Inc [NYSE: EBS] shares were valued at $9.89 at the most recent close of the market. An investor can expect a potential return of 420.73% based on the average EBS price forecast.
Analyzing the EBS fundamentals
Trailing Twelve Months sales for Emergent Biosolutions Inc [NYSE:EBS] were 851.60M which represents -44.68% decline. Gross Profit Margin for this corporation currently stands at 0.49% with Operating Profit Margin at 0.13%, Pretax Profit Margin comes in at 0.23%, and Net Profit Margin reading is 0.16%. To continue investigating profitability, this company’s Return on Assets is posted at 0.1, Equity is 0.27 and Total Capital is 0.08. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.25.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.68 points at the first support level, and at 9.47 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.09, and for the 2nd resistance point, it is at 10.29.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Emergent Biosolutions Inc [NYSE:EBS] is 5.66. In addition, the Quick Ratio stands at 3.00 and the Cash Ratio stands at 2.1. Considering the valuation of this stock, the price to sales ratio is 0.62, the price to book ratio is 0.99 and price to earnings (TTM) ratio is 4.03.
Transactions by insiders
Recent insider trading involved COLEEN GLESSNER, Officer, that happened on Oct 07 ’25 when 30608.0 shares were purchased. Director, Zoon Kathryn C completed a deal on Aug 15 ’25 to sell 7086.0 shares. Meanwhile, Director KATHRYN ZOON bought 7086.0 shares on Aug 15 ’25.
